Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate
Abstract ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds that bind the active site zinc, however, in recen...
Saved in:
Main Authors: | Franck Madoux, Daniela Dreymuller, Jean-Phillipe Pettiloud, Radleigh Santos, Christoph Becker-Pauly, Andreas Ludwig, Gregg B. Fields, Thomas Bannister, Timothy P. Spicer, Mare Cudic, Louis D. Scampavia, Dmitriy Minond |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/c6750ea01d4646cda1fe10c04ac5d8b2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Structural basis for arginine glycosylation of host substrates by bacterial effector proteins
by: Jun Bae Park, et al.
Published: (2018) -
Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide
by: Salvatore Santamaria, et al.
Published: (2021) -
Modelling of substrate access and substrate binding to cephalosporin acylases
by: Valerio Ferrario, et al.
Published: (2019) -
Comprehensive marine substrate classification applied to Canada's Pacific shelf.
by: Edward J Gregr, et al.
Published: (2021) -
Comprehensive marine substrate classification applied to Canada’s Pacific shelf
by: Edward J. Gregr, et al.
Published: (2021)